Vaccine Safety Historical Timeline
A chronological record of documented safety events and regulatory responses — 1798 to present
This timeline documents significant vaccine safety events in chronological order, along with the regulatory, scientific, and policy responses that followed each event. Every entry is sourced from named primary documents including government reports, peer-reviewed publications, court records, and agency actions.
This timeline does not characterize any event as a "failure" or a "success." It presents what happened, what the evidence showed, and how the system responded. Readers are encouraged to consult the primary sources cited for each entry to form their own assessment.
Technical terms are defined in plain language where they first appear. For additional definitions, see our Glossary.
Note: Some events are identified by their historically established names (e.g., "Lübeck Disaster," "Dengvaxia Crisis"). These names reflect common usage in medical and historical literature and do not constitute editorial characterization by VaccinationFacts.com.
Try: polio, 1976, Japan, myocarditis, withdrawal
Pre-1900
1798–1800s — Smallpox Vaccine Contamination (Various)
Event:
The earliest vaccines were produced through arm-to-arm transfer of cowpox material, a process that carried an inherent risk of transmitting other infections between patients. Documented diseases transmitted through contaminated smallpox vaccine material included syphilis, erysipelas (a bacterial skin infection), tuberculosis, and tetanus.
Response:
The contamination problem drove a transition from arm-to-arm vaccination to animal-based vaccine production (using calves). In the United States, the absence of federal regulation meant vaccine quality varied widely. It was not until the disasters of 1901 that Congress passed the Biologics Control Act of 1902.
Sources:
Wilson GS. The Hazards of Immunization. Athlone Press, 1967. Durbach N. Bodily Matters. Duke University Press, 2005.
1891 — Koch's Tuberculin Disaster
Event:
Robert Koch announced tuberculin as a cure for tuberculosis. Widespread use revealed it could cause severe reactions and death in TB patients, and did not cure the disease.
Response:
Koch's reputation was damaged. Tuberculin was eventually repurposed as a diagnostic tool (the tuberculin skin test), not a treatment.
Sources:
Daniel TM. Int J Tuberc Lung Dis, 2005;9(11):1181–1182. Gradmann C. Medical History, 2001;45:1–32.
1900–1950
1901 — St. Louis Diphtheria Antitoxin / Tetanus Deaths
Event:
A retired milk wagon horse named Jim, used to produce diphtheria antitoxin, contracted tetanus. Contaminated serum was distributed due to oversight failures including mislabeled bottles. Thirteen children died of tetanus.
Response:
Led directly to the Biologics Control Act of 1902 (P.L. 57-244), the first federal law regulating biological products in the United States.
Sources:
Lilienfeld DE. Am J Epidemiol, 2008;168(10):1065–1068. AAP. Pediatrics, 2014;133(6):964–965. FDA. "Science and the Regulation of Biological Products."
1919 — Dallas Diphtheria Antitoxin Incident
Event:
Contaminated diphtheria toxin-antitoxin (Mulford Co.) led to 5 deaths and dozens of injuries in children in Dallas, Texas.
Response:
Contributed to ongoing reform of biologics manufacturing standards.
Sources:
Wilson GS. The Hazards of Immunization. Athlone Press, 1967.
1901 — Camden, NJ Smallpox Vaccine / Tetanus Deaths
Event:
Contaminated smallpox vaccine caused tetanus in nine children in Camden, New Jersey, all of whom died.
Response:
Combined with the St. Louis incident, led to the Biologics Control Act of 1902.
Sources:
Biologics Control Act of 1902 (P.L. 57-244). Willrich M. Pox. Penguin Press, 2011.
1928 — Bundaberg Tragedy (Australia)
Event:
Diphtheria toxin-antitoxin contaminated with Staphylococcus aureus was administered to 21 children in Bundaberg, Queensland. 12 died.
Response:
Royal Commission investigation. Local immunization programs suspended. Led to changes in Australian biologics regulation.
Sources:
Wilson GS. The Hazards of Immunization. Athlone Press, 1967.
1929–1930 — Lübeck Disaster (Germany)
Event:
251 infants received oral Bacillus Calmette-Guérin (BCG) vaccine accidentally contaminated with virulent tuberculosis bacteria. 72 died; 173 developed signs of TB.
Response:
Criminal prosecution. Oral BCG discontinued worldwide. Intradermal method adopted. First International BCG Congress (1948) eventually confirmed BCG safety when properly manufactured.
1935 — Brodie and Kolmer Polio Vaccine Failures
Event:
Two experimental polio vaccines caused paralytic polio and deaths in human trials, halting polio vaccine research for over a decade.
Response:
Both vaccines abandoned. No further large-scale polio vaccine trials until Jonas Salk's work in the 1950s.
Sources:
Offit PA. The Cutter Incident. Yale University Press, 2005. Oshinsky DM. Polio: An American Story. Oxford, 2005.
1942 — Yellow Fever Vaccine / Hepatitis B Contamination (U.S. Military)
Event:
Yellow fever vaccine stabilized with pooled human serum contaminated with hepatitis B was administered to U.S. military personnel. Approximately 330,000 troops were infected; approximately 100 died.
Response:
Human serum removed from vaccine production by November 1942. Long-term follow-up (NEJM, 1987) confirmed elevated liver disease rates decades later.
Sources:
Seeff LB et al. NEJM, 1987;316(16):965–970. Norman JE et al. Hepatology, 1993;18(4):790–797.
1947 — NYC Smallpox Vaccine Encephalitis
Event:
Mass campaign vaccinated approximately 6.35 million New Yorkers. 45 cases of post-vaccinal encephalitis; 4 deaths from encephalitis; approximately 6 total vaccine-related deaths — more than the 2 deaths from the smallpox outbreak itself.
Response:
Became a frequently cited example of risk-benefit calculus in emergency vaccination campaigns.
Sources:
Weinstein L. NEJM, 1947. Belongia EA, Naleway AL. Clinical Medicine & Research, 2003;1(2):87–92.
1948 — Kyoto Diphtheria Vaccine Disaster (Japan)
Event:
Improperly detoxified diphtheria vaccine containing active toxin administered in Kyoto. 68 children died; 600+ became ill.
Response:
Major reforms in Japanese vaccine manufacturing and regulatory oversight.
1950–1980
1955 — The Cutter Incident
Event:
Cutter Laboratories released polio vaccine containing live virus. Approximately 120,000 children exposed. Estimates vary: the CDC attributed over 250 polio cases; academic reviews estimated up to 40,000 non-paralytic polio cases (a mild form not involving the central nervous system), 56–164 paralyzed, 5–10 deaths.
Response:
Vaccine recalled. Federal regulation overhauled (Division of Biologics Standards, now the Center for Biologics Evaluation and Research, or CBER, within the FDA). Gottsdanker v. Cutter established liability-without-fault precedent.
Sources:
Offit PA. Yale University Press, 2005. Nathanson & Langmuir. Am J Hygiene, 1963;78:16–81. CDC. cdc.gov/vaccine-safety/historical-concerns/
1955–1963 — SV40 Contamination of Polio Vaccines
Event:
10–30% of inactivated poliovirus vaccine (IPV) contaminated with Simian Virus 40 from monkey kidney cells. Approximately 98 million Americans exposed. SV40 caused tumors in hamsters and transformed human cells in culture.
Response:
July 26, 1961: SV40 testing mandated for all new lots. Production shifted to African green monkey cells. IOM 2002: biological plausibility but insufficient epidemiological evidence of human cancer. No vaccines used today contain SV40.
Sources:
IOM. NAP, 2002. Strickler HD et al. JAMA, 1998;279(4):292–295. CDC. cdc.gov/vaccine-safety/historical-concerns/
1955–present — Oral Polio Vaccine-Associated Paralytic Polio (VAPP) and Circulating Vaccine-Derived Poliovirus (cVDPV)
Event:
The live oral polio vaccine (OPV) can, in rare instances, revert to a form capable of causing paralytic polio. In the U.S., approximately 6–8 VAPP cases occurred annually before OPV was discontinued. In communities with low vaccination coverage, the vaccine-derived virus can spread and mutate, creating circulating vaccine-derived poliovirus (cVDPV) — a vaccine-strain virus that has regained the ability to cause paralysis and spread within under-vaccinated populations.
Response:
U.S. switched to an all-inactivated poliovirus vaccine (IPV) schedule in 2000, eliminating domestic VAPP. WHO continues OPV in endemic regions. cVDPV outbreaks remain an ongoing global challenge; a novel type 2 oral polio vaccine (nOPV2), engineered for greater genetic stability, has been deployed.
Sources:
Alexander LN et al. Pediatrics, 2004;114(4):1024–1028. CDC/ACIP. MMWR, 2000;49(RR-5):1–22. WHO. who.int (cVDPV fact sheets).
1976 — Swine Flu Vaccine and Guillain-Barré Syndrome
Event:
43 million Americans vaccinated. Guillain-Barré syndrome (GBS) — a rare disorder in which the immune system attacks the peripheral nerves, potentially causing paralysis — emerged among recipients. Approximately 450 confirmed GBS cases; approximately 1,300 suspected cases reported but not all confirmed. Risk: approximately 1 additional case per 100,000 vaccinated.
Response:
Program suspended December 16, 1976. Over 3,000 claims filed by 1980. IOM 2003 confirmed GBS association. Became foundational case study in pandemic preparedness.
Sources:
Schonberger LB et al. Am J Epidemiol, 1979;110(2):105–123. Sencer DJ, Millar JD. EID, 2006;12(1):29–33. CDC. cdc.gov/vaccine-safety/historical-concerns/
1980–2000
1974–1975 — Japan DTP Suspension
Event
Two infant deaths within 24 hours of diphtheria-tetanus-pertussis (DTP) vaccination led Japan to suspend pertussis vaccination in 1975.
Response
1979 epidemic: 13,000 cases, 40 deaths. Japan developed acellular pertussis vaccine (DTaP, containing only selected bacterial proteins rather than the whole killed organism) beginning 1981 — the first country to do so. Directly influenced global DTaP development.
Sources
Baker JP. Vaccine, 2003;21:4003–4010. Gangarosa EJ et al. Lancet, 1998;351:356–361.
1978 — National Prospective GBS Surveillance Launched
Event
CDC, the American Academy of Neurology (AAN), and the Council of State and Territorial Epidemiologists (CSTE) established national prospective surveillance for GBS following influenza vaccination, in direct response to the 1976 experience.
Response
Provided infrastructure for future GBS signal detection. Informed the design of the Vaccine Adverse Event Reporting System (VAERS, launched 1990) and the Vaccine Safety Datalink (VSD).
Sources
Hurwitz ES et al. NEJM, 1981;304:1557–1561. IOM. Influenza Vaccines and Neurological Complications. NAP, 2004.
1982 — "DPT: Vaccine Roulette" Documentary
Event
WRC-TV documentary depicted children with disabilities attributed to the whole-cell DTP vaccine. The program was a media portrayal of parental concerns, not a clinical study, but it generated extensive public alarm. Led to founding of the National Vaccine Information Center (NVIC) and surge in litigation.
Response
Vaccine prices rose from approximately $0.11 to $11/dose. All but one manufacturer exited by 1985.
Sources
WRC-TV, 1982. Coulter & Fisher. DPT: A Shot in the Dark, 1985.
1986 — National Childhood Vaccine Injury Act (NCVIA)
Event
Congress passed NCVIA (42 U.S.C. §§ 300aa-1–34) in response to the litigation crisis threatening vaccine supply.
Response
Established the Vaccine Injury Compensation Program, or VICP (a no-fault system designed to ensure families could receive compensation quickly without the costs and delays of traditional lawsuits), the Vaccine Adverse Event Reporting System (VAERS), and Vaccine Information Statement (VIS) requirements. Led to Bruesewitz v. Wyeth (2011) fully shielding manufacturers.
1990 — Establishment of VAERS and the Vaccine Safety Datalink
Event
VAERS (a reporting system that collects possible vaccine problems after vaccination) and VSD (an active monitoring system that links vaccination records with medical outcomes to study possible patterns) launched, fulfilling NCVIA mandates.
Response
Became the foundation of U.S. post-market vaccine safety monitoring. VAERS detects signals rapidly; VSD provides statistical rigor to evaluate them.
Sources
42 U.S.C. §§ 300aa-1–34. CDC. vaers.hhs.gov. Shimabukuro TT et al. Vaccine, 2015;33(36):4398–4405.
1991 — Gulf War Squalene Controversy
Event
Reports of squalene antibodies in ill Gulf War veterans led to allegations of secret experimental adjuvant (an ingredient added to a vaccine to strengthen the immune response) use. The Department of Defense denied squalene was used in any deployed vaccines.
Response
GAO investigated. No causal link established. FDA found only trace squalene consistent with manufacturing contamination, not deliberate addition.
Sources
GAO Report NSIAD-99-5, 1999. Asa PB et al. Experimental and Molecular Pathology, 2000;68:55–64.
1991–2000s — Anthrax Vaccine Controversy (U.S. Military)
Event
Mandatory anthrax vaccination for military personnel. Reports of adverse reactions and refusals. Some service members faced court-martial.
Response
Doe v. Rumsfeld (2003): Federal court ruled mandatory vaccination without full FDA licensure for the specific use (inhalation anthrax) was illegal. Program halted. FDA granted supplemental license in 2008.
Sources
Doe v. Rumsfeld, 297 F. Supp. 2d 119 (D.D.C. 2003). IOM. The Anthrax Vaccine: Is It Safe? Does It Work? NAP, 2002.
1992 — Brazil MMR Urabe-Strain Withdrawal
Event
Outbreaks of aseptic meningitis (inflammation of the tissues around the brain and spinal cord that is not caused by bacterial infection) following Urabe AM9 mumps strain measles-mumps-rubella (MMR) vaccines led to national product withdrawal.
Response
Urabe strain replaced by Jeryl Lynn strain globally. Similar withdrawals in UK (1992) and Japan (1993). Highlighted strain-specific safety differences.
Sources
Dourado I et al. Am J Epidemiol, 2000;151(5):524–530. Miller E et al. Lancet, 1993;341:979–982.
1992–1994 — Marginal GBS Signal in Seasonal Influenza Vaccine
Event
Population-based surveillance detected approximately 1 additional GBS case per million influenza vaccine recipients.
Response
Risk magnitude (approximately 1 per million) was far below the 1976 signal (approximately 1 per 100,000). No changes to vaccination recommendations. Demonstrated modern surveillance sensitivity.
Sources
Lasky T et al. NEJM, 1998;339(25):1797–1802. IOM. NAP, 2004.
1998 — Wakefield MMR-Autism Paper Published
Event
Lancet paper suggested MMR-autism link based on 12 cases. UK uptake dropped below 80%. Measles outbreaks followed.
Response
Paper retracted 2010. Wakefield's license revoked. Omnibus Autism Proceeding (OAP) test cases (2009–2010) ruled against all petitioners; 5,000+ claims dismissed. Multiple large studies found no association.
Sources
Wakefield et al. Lancet, 1998 [RETRACTED]. Deer B. BMJ, 2011;342:c5347. Madsen KM et al. NEJM, 2002;347(19):1477–1482.
1998 — Hepatitis B Vaccine / Multiple Sclerosis Concerns (France)
Event
French researchers reported possible hepatitis B vaccine-MS association. France suspended school-based hepatitis B vaccination in October 1998.
Response
IOM 2002: no causal link. WHO reaffirmed safety. Ascherio et al. (NEJM, 2001) found no increased MS risk. France eventually resumed.
Sources
IOM. NAP, 2002. Ascherio A et al. NEJM, 2001;344(5):327–332.
1998 — Macrophagic Myofasciitis (MMF) Discovery
Event
French researchers described persistent aluminum-containing lesions at injection sites. Some researchers proposed systemic symptoms.
Response
WHO GACVS concluded MMF is a local finding seen under the microscope in tissue samples, not evidence of systemic disease. Remains a subject of scientific debate — a proposed association under investigation, not an established condition.
Sources
Gherardi RK et al. Brain, 2001;124(Pt 9):1821–1831. WHO GACVS Statement, 1999.
1998–1999 — Thimerosal Review and Removal from Childhood Vaccines
Event
FDA review found cumulative ethylmercury from thimerosal could exceed Environmental Protection Agency (EPA) methylmercury guidelines (though the two forms have different properties). The American Academy of Pediatrics and the U.S. Public Health Service (AAP/PHS) recommended precautionary removal.
Response
Thimerosal removed from most childhood vaccines by 2001. IOM 2004: evidence favors rejection of thimerosal-autism link. Autism rates continued rising after removal. Remains in some multi-dose flu vials.
Sources
FDA, 1999. IOM. NAP, 2004. Thompson WW et al. NEJM, 2007;357(13):1281–1292.
1998–2002 — LYMErix Withdrawal (Lyme Disease Vaccine)
Event
First human Lyme vaccine (approximately 78% effective after 3 doses). Reports of arthritis in VAERS. Class-action lawsuit filed (1999). Sales dropped from approximately 1.5 million doses (1999) to approximately 10,000 (2002).
Response
GSK withdrew LYMErix February 2002. Settled lawsuit ($1M+ legal fees, no victim compensation). FDA never found a safety problem. Pre- and post-licensure data showed no excess arthritis. No human Lyme vaccine available since.
Sources
Nigrovic LE, Thompson KM. Epidemiology & Infection, 2007;135(1):1–8. Aronowitz RA. Milbank Quarterly, 2012;90(2):250–283.
1999 — RotaShield Withdrawal (Intussusception)
Event
First rotavirus vaccine. Rotavirus is a leading cause of severe diarrhea and dehydration in infants worldwide. 98 confirmed cases of intussusception — a serious condition where one part of the intestine slides into the next, like a collapsing telescope — among approximately 500,000 vaccinated infants.
Response
The Advisory Committee on Immunization Practices (ACIP) withdrew recommendation October 22, 1999. Wyeth voluntarily withdrew. Led to 60,000+ subject trials for successor vaccines (RotaTeq, Rotarix).
1999 — ACIP All-IPV Recommendation (Ending OPV Use in the U.S.)
Event
The Advisory Committee on Immunization Practices (ACIP) recommended all-IPV schedule because the only remaining U.S. polio cases were vaccine-caused (VAPP, approximately 6–8/year).
Response
Transition completed 2000. VAPP eliminated domestically. First time U.S. switched vaccines solely because the safety profile had become unacceptable relative to the changed disease environment.
Sources
CDC/ACIP. MMWR, 2000;49(RR-5):1–22. Alexander LN et al. Pediatrics, 2004;114(4):1024–1028.
2000–Present
2000 — BSE Precautionary Vaccine Regulation
Event
FDA requested manufacturers phase out bovine-derived materials from countries affected by bovine spongiform encephalopathy (BSE, commonly known as mad cow disease). No confirmed BSE transmission via vaccines had occurred; the action was a theoretical precaution.
Response
Manufacturers reformulated products. No confirmed cases of BSE or variant Creutzfeldt-Jakob disease (vCJD) transmission through vaccines were ever identified.
2000–2017 — India OPV / NPAFP Controversy
Event
Researchers observed elevated rates of non-polio acute flaccid paralysis, or NPAFP (sudden limb weakness not caused by wild poliovirus), during intensive Pulse Polio campaigns in India.
Response
Findings remain contested. India certified polio-free 2014. Some researchers attribute elevated NPAFP to improved surveillance; others argue a biological signal exists.
Sources
Vashisht N, Puliyel J. Indian J Med Ethics, 2012;9(2):114–117.
2001 — Launch of the CISA Network
Event
CDC established the Clinical Immunization Safety Assessment (CISA) network for expert clinical evaluation of complex individual adverse events.
Response
Became a key component of U.S. vaccine safety infrastructure for case-level assessment.
2001–2003 — Smallpox Vaccine / Myopericarditis (Post-9/11)
Event
Post-9/11 smallpox vaccination for military and first responders. Myopericarditis (inflammation of the heart muscle and surrounding tissue) at approximately 1 per 12,000 first-time vaccinees.
Response
Civilian program scaled back. Newer vaccine (ACAM2000) carries similar warning.
2003 — Northern Nigeria Polio Vaccine Boycott
Event
Political and religious leaders in Kano and other northern states alleged OPV contained anti-fertility agents. Year-long boycott.
Response
The boycott had significant public health consequences: polio surged in Nigeria and spread to 20+ previously polio-free countries. The Organisation of Islamic Cooperation (OIC) mediated. Independent testing confirmed vaccine safety.
Sources
Jegede AS. PLoS Medicine, 2007;4(3):e73. Yahya M. African Affairs, 2007;106(423):185–204.
2004 — Japan Suspends JE Vaccine Recommendation
Event
Japan suspended proactive recommendation for mouse-brain-derived Japanese encephalitis vaccine following reports of ADEM — acute disseminated encephalomyelitis, a rare inflammatory condition in which the immune system attacks the protective covering of nerve fibers in the brain and spinal cord.
Response
Vaccine remained available on request. Japan later transitioned to cell culture-derived JE vaccine.
2005–2008 — Menactra / GBS Investigation
Event
Reports of GBS in adolescents after Menactra meningococcal vaccine. CDC investigated.
Response
Two large studies (approximately 2M adolescents) found no link. Vaccine continued. Demonstrated post-market system working as designed.
Sources
CDC. cdc.gov/vaccine-safety/. Velentgas P et al. Pharmacoepidemiology and Drug Safety, 2012.
2006–present — Gardasil (HPV) Safety Debate
Event
Human papillomavirus (HPV) vaccine generated safety concerns (reports of postural orthostatic tachycardia syndrome, or POTS, a condition affecting heart rate and blood pressure upon standing; and complex regional pain syndrome, or CRPS, a chronic pain condition) and social controversy. Japan suspended proactive recommendation 2013–2022.
Response
Large studies found no increased autoimmune risk. Japan reinstated 2022. WHO reaffirmed safety.
Sources
Arnheim-Dahlström L et al. BMJ, 2013;347:f5906. WHO GACVS statements on HPV vaccine safety.
2007 — Hib Vaccine Recall (B. cereus Contamination)
Event
Merck recalled approximately 1.2M doses of Haemophilus influenzae type b (Hib) vaccine for potential B. cereus contamination, identified through quality testing.
Response
Precautionary recall. No infections found. Temporary Hib shortage required modified dosing schedules.
2007 — Vietnam Hepatitis B Vaccine Suspension
Event
National suspension of birth-dose hepatitis B vaccine after infant deaths. Investigation determined deaths were coincidental (sudden infant death syndrome, or SIDS, and other causes).
Response
Program resumed after WHO review.
2009 — India PATH/HPV Investigation
Event
Indian Parliamentary investigation into PATH-led HPV project found procedural violations in consent and monitoring, though no safety issues were confirmed with the vaccine itself.
Response
Led to clinical trial oversight reforms in India. Delayed HPV vaccine introduction.
Sources
Larson HJ et al. Vaccine, 2011. Indian Parliament Standing Committee, 72nd Report, 2013.
2009–2010 — Pandemrix and Narcolepsy
Event
GSK's Pandemrix (an H1N1 vaccine containing an immune-boosting ingredient called an adjuvant, specifically AS03) used widely in Europe. 9x increased narcolepsy risk in vaccinated Finnish children. Narcolepsy is a disorder of excessive daytime sleepiness; cataplexy is a sudden loss of muscle control often triggered by strong emotions. 152+ cases in Finland.
Response
EMA restricted use 2011. Never used in U.S. A molecular mimicry mechanism was proposed in 2018, meaning the immune response may have mistakenly attacked a normal brain protein because of structural similarity to a component in the vaccine. No longer in use.
Sources
Nohynek H et al. PLoS ONE, 2012;7(3):e33536. Miller E et al. BMJ, 2013;346:f794. ECDC, 2012.
2010 — Rotavirus Vaccine / Porcine Circovirus DNA Contamination
Event
Porcine circovirus type 1 (PCV-1) DNA detected in Rotarix; PCV-1 and porcine circovirus type 2 (PCV-2) fragments in RotaTeq. FDA temporarily suspended Rotarix.
Response
FDA advisory committee: PCV poses no safety risk to humans. Both vaccines returned to full use.
Sources
FDA Safety Communication, March 2010. Victoria JG et al. J Virol, 2010;84(12):6033–6040.
2011 — ASIA Syndrome Hypothesis Proposed
Event
Immunologist Yehuda Shoenfeld proposed Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA) as a unifying concept for autoimmunity potentially triggered by adjuvants, ingredients added to some vaccines to strengthen the immune response.
Response
Remains a proposed hypothesis under scientific debate, not an established clinical diagnosis. WHO GACVS has not endorsed ASIA as a recognized entity.
Sources
Shoenfeld Y, Agmon-Levin N. J Autoimmunity, 2011;36(1):4–8. Ameratunga R et al. JACI: In Practice, 2017;5(6):1551–1555.
2012 — Quinvaxem Pentavalent Vaccine Suspensions
Event
Multiple countries (Vietnam, Bhutan, Sri Lanka, India) suspended Quinvaxem after clusters of post-vaccination infant deaths.
Response
The WHO's Global Advisory Committee on Vaccine Safety (GACVS) concluded that the evidence did not support a causal link and that the reported deaths were consistent with expected background infant mortality. Most countries resumed use.
2013 — Gardasil Recall (Glass Particle Contamination)
Event
Merck recalled one Gardasil lot for possible glass particles from manufacturing error.
Response
Precautionary recall. No health problems reported. Quality control system functioning as designed.
2014 — CDC Whistleblower Allegations
Event
CDC scientist William Thompson alleged data omission from a 2004 study regarding MMR timing and autism in a subgroup of African American boys.
Response
CDC stated methodology was appropriate. Hooker (2014) reanalysis was retracted. No investigation found misconduct. Multiple large studies found no MMR-autism link.
Sources
DeStefano F et al. Pediatrics, 2004;113(2):259–266. Hooker BS. Translational Neurodegeneration, 2014 [RETRACTED].
2014 — Syria Measles Vaccine Diluent Error
Event
In Idlib province, healthcare workers used atracurium (a muscle relaxant) as vaccine diluent instead of sterile water. 15 children died.
Response
WHO issued global alert. The incident highlighted the extreme dangers of vaccine administration in conflict zones with collapsed infrastructure.
2017 — Dengvaxia Crisis (Philippines)
Event
830,000+ Filipino schoolchildren vaccinated with Dengvaxia. Sanofi announced increased severe dengue risk in seronegative (never previously infected) recipients. The announcement led to political controversy and a significant decline in public vaccine confidence.
Response
Philippines suspended program. Criminal charges filed. Vaccine confidence dropped from 93% to 32% (Vaccine Confidence Project). Measles outbreaks followed as parents refused routine vaccines. Philippines permanently withdrew Dengvaxia 2024. Approved in EU/US only for seropositive individuals.
Sources
Larson HJ et al. Hum Vaccin Immunother, 2019;15(3):625–627. Mendoza RU et al. SSRN, 2020. WHO. WER, 2018;93(36):457–476.
2018 — China Vaccine Scandal (Changchun Changsheng)
Event
Government inspection revealed falsified quality control data for rabies vaccine and 252,600 substandard DTP doses. The revelation generated significant public concern across China.
Response
Executives arrested and sentenced. Company fined 9.1 billion yuan (approximately $1.3B). China enacted new Vaccine Administration Law (2019) with strict penalties and electronic tracking.
Sources
China State Council Investigation, 2018. The Lancet editorial, 2018;392(10145):372.
2018 — Samoa MMR Diluent Deaths and 2019 Measles Epidemic
Event
Two infants died after nurses mixed MMR vaccine with incorrect diluent (a muscle relaxant). The deaths caused by preparation error, not the vaccine. MMR program suspended. Vaccination rates declined.
Response
Nurses convicted. In late 2019, Samoa experienced a large measles epidemic: 5,700+ cases, 83 deaths (mostly children under 5) in a population of approximately 200,000. The Samoa episode is studied as a case where a single preparation error, amplified by public fear, led to catastrophic public health consequences.
Sources
WHO Joint Statement, 2018. Craig AT et al. Lancet Infect Dis, 2020.
2019 — Peshawar Polio Vaccine Panic (Pakistan)
Event
False rumors that children were fainting after OPV led to approximately 25,000 hospitalizations from panic. Civil unrest including damage to a healthcare facility occurred.
Response
Authorities determined hospitalizations resulted from mass psychogenic illness — a phenomenon in which anxiety and fear produce real physical symptoms (dizziness, nausea, fainting) in groups of people, in the absence of a toxic or infectious cause. No children harmed by the vaccine. The incident highlighted the serious impact of misinformation on vaccination programs.
2020 — Launch of V-safe Active Surveillance System
Event
CDC launched V-safe, a smartphone-based active surveillance tool for COVID-19 vaccine recipients.
Response
10+ million enrolled — largest active vaccine safety surveillance in U.S. history. Contributed to safety monitoring during pregnancy and identification of reactogenicity patterns (expected short-term reactions such as soreness, fatigue, fever, or headache after vaccination).
Sources
Shimabukuro TT et al. NEJM, 2021. CDC. cdc.gov/coronavirus/.
2020–2021 — COVID-19 mRNA Vaccines: Myocarditis/Pericarditis
Event
Elevated risk of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the tissue surrounding the heart), predominantly in males aged 16–29 after second dose of Pfizer or Moderna mRNA vaccines.
Response
FDA added warning labels. The CDC maintained its recommendation for COVID-19 vaccination across most age groups, while acknowledging that risk-benefit considerations vary by age and individual health status.
Sources
Oster ME et al. JAMA, 2022;327(4):331–340. Mevorach D et al. NEJM, 2021;385:2140–2149.
2021 — COVID-19 Adenoviral Vaccines: Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT)
Event
Rare but serious condition — unusual blood clots combined with dangerously low platelet counts — identified with J&J/Janssen and AstraZeneca adenoviral vector vaccines, primarily in younger women.
Response
ACIP paused J&J April 13, 2021. Multiple countries restricted AstraZeneca. In June 2023, at the manufacturer's request, the FDA revoked the J&J emergency use authorization (EUA) as all remaining doses had expired and no further demand existed.
Sources
See I et al. JAMA, 2021;325(24):2448–2456. Greinacher A et al. NEJM, 2021;384:2092–2101. FDA News Release, June 1, 2023.
2021 — AstraZeneca COVID-19 Vaccine Suspensions in Europe
Event
Multiple European countries suspended or restricted AstraZeneca following VITT reports. Fragmented responses created public confusion.
Response
The EMA concluded that overall benefits outweighed risks but added VITT as a very rare side effect. Denmark and Norway permanently dropped AstraZeneca.
Sources
EMA Safety Assessment, April 7, 2021. Pottegård A et al. BMJ, 2021;373:n1114.
2022 — Novavax COVID-19 Vaccine Myocarditis Signal
Event
Post-authorization myocarditis/pericarditis signal detected with Novavax protein subunit vaccine.
Response
FDA included myocarditis warning in EUA fact sheet. Early surveillance summaries suggested lower reported rates than those observed after mRNA vaccination, but direct comparison remained difficult because Novavax was used in far smaller numbers.
2023–2024 — RSV Vaccine (Arexvy) and Guillain-Barré Syndrome Signal
Event
Post-market surveillance detected potential GBS signal with GSK's Arexvy respiratory syncytial virus (RSV) vaccine in adults 60+.
Response
FDA added GBS warning. ACIP recommended shared clinical decision-making rather than universal recommendation.
Sources
FDA Safety Communication, 2023. ACIP Meeting Notes, 2023.
Ongoing — Freeze-Thaw Supply Chain Failures
Event
Documented incidents of vaccines exposed to freezing during transport, potentially reducing effectiveness and increasing local reactogenicity (injection site pain and swelling). A 2007 review found up to 75% of shipments in some settings were exposed to freezing.
Response
WHO/UNICEF issued guidance. Freeze indicators and controlled temperature chain protocols developed.
Sources
Matthias DM et al. Vaccine, 2007;25(20):3980–3986. Kartoglu U, Milstien J. Expert Rev Vaccines, 2014;13(7):843–854.
Editorial Note
This timeline presents documented events and their documented responses. It does not editorialize on whether any response was adequate, timely, or appropriate. Readers are encouraged to consult the primary sources cited.
61 documented events. All entries sourced from named primary documents.